What is the cost-effectiveness of dry eye syndrome
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Cost-Effectiveness of Dry Eye Syndrome Treatments
Introduction to Dry Eye Syndrome and Economic Impact
Dry eye syndrome (DES) is a prevalent ocular condition that significantly impacts patients' quality of life and imposes a substantial economic burden on healthcare systems globally. The cost-effectiveness of various treatments for DES is a critical consideration for both healthcare providers and patients.
Cost-Effectiveness of Topical Cyclosporine
Topical cyclosporine (Restasis) has been evaluated for its cost-effectiveness in treating moderate to severe DES unresponsive to conventional therapy. Studies show that topical cyclosporine provides a quality-adjusted life-year (QALY) gain of 0.0319 per year and a 4.3% improvement in quality of life compared to lubricant therapy. The societal perspective incremental cost-utility ratio (CUR) for cyclosporine is $34,953 per QALY, and the average CUR is $11,199 per QALY. From a third-party insurer perspective, the incremental CUR is $37,179 per QALY, and the average CUR is $34,343 per QALY, indicating that cyclosporine is a cost-effective treatment option for DES.
Annual Costs of Managing Dry Eye Syndrome in Europe
In Europe, the annual cost of managing DES varies significantly across countries. For instance, the total annual healthcare cost for 1,000 DES patients managed by ophthalmologists ranges from $0.27 million in France to $1.10 million in the UK. This variation highlights the economic burden of DES on healthcare systems, although many patients self-treat with over-the-counter medications, which were not captured in this analysis.
Economic Burden in Canada
In Canada, the direct and indirect costs of DES increase with disease severity. The total mean annual cost per patient is approximately $24,331 CAD, with indirect costs being significantly higher than direct costs. Patients with severe DES incur higher costs and experience a greater reduction in quality of life compared to those with mild or moderate disease.
Economic Burden in the United States
In the United States, the average annual cost of managing a DES patient is $783 from the payer's perspective and $11,302 from a societal perspective. The overall burden of DES on the US healthcare system is estimated at $3.84 billion, with a total societal cost of $55.4 billion. These figures underscore the substantial economic impact of DES on both healthcare systems and society.
Cost-Effectiveness of Ophthalmic Lubricants
A comparative study of two ophthalmic lubricants, Systane® and Refresh Tears®, found that Systane® is more effective in improving symptoms of dryness, with an incremental cost-effectiveness ratio (ICER) of $5,837 per QALY. Both lubricants are considered cost-effective, but Systane® offers greater clinical benefits despite its higher cost.
Conclusion
The cost-effectiveness of DES treatments varies depending on the therapy and the healthcare system. Topical cyclosporine and ophthalmic lubricants like Systane® and Refresh Tears® are effective and cost-effective options for managing DES. However, the economic burden of DES remains significant, emphasizing the need for efficient management strategies to reduce costs and improve patient outcomes.
Sources and full results
Most relevant research papers on this topic